Organotin-induced caspase activation and apoptosis in human peripheral blood lymphocytes.
In the present study, we show that the immunotoxicant, tributyltin (TBT), induces a dose-dependent activation of caspases followed by typical apoptotic morphology in resting human peripheral blood lymphocytes. TBT also caused an early loss of mitochondrial membrane potential (Delta(Psi)(m)) and release of cytochrome c, suggesting that apoptosis was triggered by the mitochondrial pathway. When CD4+ T-cells were sorted from peripheral blood and exposed to TBT for 30 min, caspase activation and apoptosis were induced. Interestingly, in the sorted CD8+ T-cell population, caspase activation was not observed until 2 h of TBT exposure, suggesting that these cells were more resistant toward TBT. Moreover, a time-dependent induction of caspase activity was also detected in CD3-stimulated peripheral blood lymphocytes. This caspase activation was not associated with cytochrome c release or loss of mitochondrial Delta(Psi) and did not lead to apoptotic morphology, although it did lead to both PARP and DFF cleavage. We also noticed a concomitant induction of Hsp27, and it awaits to be seen if this chaperone may interfere with the processing of nuclear protein substrates downstream from these primary caspase-3 substrates. Moreover, no increase in caspase activation or induction of apoptosis was observed after TBT treatment in these cells. Instead, the cells were directed toward necrotic deletion. Taken together, these data suggest that TBT-induced deletion of peripheral lymphocytes is likely to be a component in the overall risk for immunotoxic responses in exposed humans.
Stridh
H
H
Institute of Environmental Medicine, Department of Medicine, Division of Respiratory Medicine, Karolinska Institutet, Stockholm, Sweden. helene.stridh@ks.se
Cotgreave
I
I
Müller
M
M
Orrenius
S
S
Gigliotti
D
D
D017209:Apoptosis / Q000187:drug effects*; D017252:CD3 Complex / Q000097:blood / Q000276:immunology / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D020169:Caspases / Q000378:metabolism*; D003574:Cytochrome c Group / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D006801:Humans; D007700:Kinetics; D008214:Lymphocytes / Q000097:blood / Q000187:drug effects* / Q000201:enzymology; D008564:Membrane Potentials; D008928:Mitochondria / Q000187:drug effects; D009947:Organotin Compounds / Q000494:pharmacology*; D014220:Trialkyltin Compounds / Q000494:pharmacology*
D017252:CD3 Complex; D003574:Cytochrome c Group; D009947:Organotin Compounds; D014220:Trialkyltin Compounds; C011559:tributyltin; D020169:Caspases